AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

15.390

+0.5503.71%

Volume:660.57K

Turnover:10.08M

Market Cap:1.89B

PE:14.17

High:15.495

Open:15.000

Low:14.910

Close:14.840

Loading ...

Overview Company News Filings

Notification regarding unquoted securities - NEU-NEU.AX

Neuren Shares Rise, CSL Inches Down After Trump Flags Tariffs on Pharmaceuticals

MT Newswires Live

Application for quotation of securities - NEU-NEU.AX

Bell Potter names more of the best ASX 200 shares to buy in FY26

ASX Midday Sector Update: Healthcare Stocks Inch Up, Information Technology Sector Retreats

MT Newswires Live

BUZZ-Australia's Neuren Pharmaceuticals jumps on drug patent approval in US

Neuren Pharmaceuticals - US Patent Allowed for Nnz-2591 to Treat Pitt Hopkins

THOMSON REUTERS

ASX ALERT-US patent allowed for NNZ-2591 to treat Pitt Hopkins-NEU.AX

Notification of cessation of securities - NEU-NEU.AX

These ASX 200 shares could rise 40% to 50%

5 things to watch on the ASX 200 on Friday

Here are the top 10 ASX 200 shares today

Neuren Pharmaceuticals Grants Share Options After FDA Meeting

MT Newswires Live

Saudi Aramco Signs 34 MoUs, Agreements With US Companies

MT Newswires Live

Neuren Confirms Receipt of US FDA Meeting Minutes for Trial; Shares Rise 3%

MT Newswires Live

Neuren Pharmaceuticals Partner Posts 11% Surge in Rett Syndrome Drug Sales in Q1

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Says Daybue Q1 2025 Net Sales $84.6 Million

Neuren Pharmaceuticals Ltd - Daybue Q1 2025 Net Sales US$84.6 Mln

THOMSON REUTERS

Here are the top 10 ASX 200 shares today

Neuren Pharmaceuticals Appoints Chief Regulatory Officer; Shares Up 8%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":15.39,"timestamp":1752819120000,"preClose":14.84,"halted":0,"volume":660569,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":106722783,"shares":122989526,"eps":1.086099,"marketStatus":"Market Closed","change":0.55,"latestTime":"07-18 16:12:00 AEST","open":15,"high":15.495,"low":14.91,"amount":10082361,"amplitude":0.03942,"askPrice":15.39,"askSize":1224,"bidPrice":15.1,"bidSize":10,"shortable":3,"etf":0,"ttmEps":1.086099,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":14.84,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":2.0703494252070067,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":106722783,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":2.0703494252070067,"shares":122989526,"dividePrice":0,"high":15.495,"amplitude":0.03942,"preClose":14.84,"low":14.91,"week52Low":8.61,"pbRate":"5.20","psRate":"8.73","week52High":21.285,"institutionHeld":0,"latestPrice":15.39,"committee":-0.983793,"eps":1.086099,"divideRate":0,"volume":660569,"delay":0,"ttmEps":1.086099,"open":15,"prevYearClose":12.5,"prevWeekClose":14.57,"prevMonthClose":14.11,"prevQuarterClose":14.11,"fiveDayClose":14.57,"twentyDayClose":12.54,"sixtyDayClose":11.01},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550685875","title":"Notification regarding unquoted securities - NEU-NEU.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550685875","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550685875?lang=en_us&edition=fundamental","pubTime":"2025-07-09 15:03","pubTimestamp":1752044621,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX8rr25X","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASXbKl5RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2550577585","title":"Neuren Shares Rise, CSL Inches Down After Trump Flags Tariffs on Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2550577585","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550577585?lang=en_us&edition=fundamental","pubTime":"2025-07-09 09:14","pubTimestamp":1752023667,"startTime":"0","endTime":"0","summary":"Shares of Neuren Pharmaceuticals  rose almost 1% in early trading on Wednesday, while those of CSL  were marginally lower, following US President Donald Trump's remarks on tariffs on the pharmaceutical industry on Tuesday.Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the US \"very soon,\" adding that he will \"give people about a year, year and a half,\" CNBC reported.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4086","CSL","BK7067","NEU.AU","LU1169590202.USD","BK7096","SGXZ23171101.USD","LU0728928796.USD","CSL.AU","BK7501","BK7511","LU1169589451.USD","SG9999004303.SGD","BK7508"],"gpt_icon":0},{"id":"2547706844","title":"Application for quotation of securities - NEU-NEU.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547706844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547706844?lang=en_us&edition=fundamental","pubTime":"2025-06-30 15:49","pubTimestamp":1751269768,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX56Ql18","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX6G8TR9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2546676954","title":"Bell Potter names more of the best ASX 200 shares to buy in FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2546676954","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546676954?lang=en_us&edition=fundamental","pubTime":"2025-06-27 09:18","pubTimestamp":1750987122,"startTime":"0","endTime":"0","summary":"The team at Bell Potter has been running the rule over the Australian share market ahead of the new financial year. This has seen the broker pick out its best buys for the year ahead. We have already ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/06/27/bell-potter-names-more-of-the-best-asx-200-shares-to-buy-in-fy26/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ALQ.AU","BK7050","NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2546745592","title":"ASX Midday Sector Update: Healthcare Stocks Inch Up, Information Technology Sector Retreats","url":"https://stock-news.laohu8.com/highlight/detail?id=2546745592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546745592?lang=en_us&edition=fundamental","pubTime":"2025-06-26 11:27","pubTimestamp":1750908473,"startTime":"0","endTime":"0","summary":"Healthcare was one of the only three sectors trading in the green on the ASX at midday Thursday, at 0.5%.Neuren Pharmaceuticals  said the US Patent and Trademark Office allowed its application covering the use of NNZ-2591 to treat Pitt-Hopkins syndrome, a rare genetic condition, to be issued as a patent. Once issued, the patent is set to expire in April 2040. Its shares soared over 9% in recent trading.On the flip side, the information technology sector fell almost 2%, dragged down by sector heavyweight Xero , which fell almost 5% in recent trade.The software giant received commitments to raise AU$1.85 billion through the placement of 10.5 million shares at AU$176 apiece. The proceeds will fund the company's acquisition of fintech firm Melio and its associated entities, along with transaction costs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4134","BK7503","III","NEU.AU","BK7016","BK4137","BK7096","HCSG","XRO.AU","BK7508"],"gpt_icon":0},{"id":"2546279378","title":"BUZZ-Australia's Neuren Pharmaceuticals jumps on drug patent approval in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2546279378","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546279378?lang=en_us&edition=fundamental","pubTime":"2025-06-26 10:30","pubTimestamp":1750905011,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals jumps on drug patent approval in US ** Shares of Neuren Pharmaceuticals NEU.AX rise 11% to A$13.92, their highest since June 13** Stock is the top gainer on the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nL4N3ST04Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2546822497","title":"Neuren Pharmaceuticals - US Patent Allowed for Nnz-2591 to Treat Pitt Hopkins","url":"https://stock-news.laohu8.com/highlight/detail?id=2546822497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546822497?lang=en_us&edition=fundamental","pubTime":"2025-06-26 07:25","pubTimestamp":1750893944,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS0IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2546222896","title":"ASX ALERT-US patent allowed for NNZ-2591 to treat Pitt Hopkins-NEU.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546222896","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546222896?lang=en_us&edition=fundamental","pubTime":"2025-06-26 07:25","pubTimestamp":1750893926,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nASX4qg81b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nASX3TBzyd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2546296758","title":"Notification of cessation of securities - NEU-NEU.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546296758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546296758?lang=en_us&edition=fundamental","pubTime":"2025-06-25 15:26","pubTimestamp":1750836391,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nASX3SkFBL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nASXbR7xyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2545434621","title":"These ASX 200 shares could rise 40% to 50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545434621","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545434621?lang=en_us&edition=fundamental","pubTime":"2025-06-22 05:43","pubTimestamp":1750542180,"startTime":"0","endTime":"0","summary":"If you are wanting to supercharge your portfolio returns, then it could be worth looking at the ASX 200 shares in this article. They have been named as buys by Macquarie and tipped to rise around 40% ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/06/22/these-asx-200-shares-could-rise-40-to-50/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7046","BK7070","BK7503","MQG.AU","WEB.AU","BK7511","WTC.AU","BK7508","BK7016","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2543523866","title":"5 things to watch on the ASX 200 on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2543523866","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543523866?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:47","pubTimestamp":1749761238,"startTime":"0","endTime":"0","summary":"On Thursday, theS&P/ASX 200 Index was out of form and dropped into the red. The benchmark index fell 0.3% to 8,565.1 points. Will the market bounce back from this on Friday and end the week on a high?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/06/13/5-things-to-watch-on-the-asx-200-on-friday-13-june-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7507","XJO.AU","BK7040","KAR.AU","NEU.AU","BK7104","NST.AU","EDV.AU","STO.AU","BK7506","EVN.AU","BK7096","BK7142"],"gpt_icon":0},{"id":"2539232514","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2539232514","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539232514?lang=en_us&edition=fundamental","pubTime":"2025-05-29 14:54","pubTimestamp":1748501651,"startTime":"0","endTime":"0","summary":"It was a mildly positive session for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares this Thursday, building on the incremental gains we saw yesterday. By the time trading wrapped up, the ASX 200","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/29/here-are-the-top-10-asx-200-shares-today-29-may-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7135","BK7043","WDS.AU","BK7051","AOV.AU","BK7504","BK7142","JDO.AU","CSC.AU","NEU.AU","MP1.AU","LTR.AU","BK7503","BK7093","BK7096","ZIP.AU","BK7095","NIC.AU","BK7110","XYZ.AU","BK7158","BK7508"],"gpt_icon":0},{"id":"2537908759","title":"Neuren Pharmaceuticals Grants Share Options After FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537908759","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537908759?lang=en_us&edition=fundamental","pubTime":"2025-05-23 11:37","pubTimestamp":1747971421,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  has approved the issue of new 2.16 million share options as a long-term incentive at an exercise price of AU$12.91, according to a Friday Australian bourse filing.The issue follows its meeting with the US Food and Drug Administration for Phelan-McDermid syndrome, a neurodevelopmental disorder for which it's developing its drug candidate NNZ-2591.The exercise price is equal to the volume-weighted average price of trading during the five days before the issue, and the options expire five years after the issue.Out of the total, 360,000 options for Chief Executive Officer Jon Pilcher will be subject to shareholder approval and will not be issued before receiving said approval at a future meeting.The company will vest one-third of the options upon each of the following milestones: completion of last patient dosing in a Phase 3 trial, acceptance for filing of a marketing application or completion of a major partnership deal, and first patient dosing in a pivotal trial","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2535072136","title":"Saudi Aramco Signs 34 MoUs, Agreements With US Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2535072136","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535072136?lang=en_us&edition=fundamental","pubTime":"2025-05-14 23:55","pubTimestamp":1747238148,"startTime":"0","endTime":"0","summary":"Saudi Aramco said Wednesday it has signed 34 memoranda of understanding and agreements worth potentially about $90 billion with US companies via its Aramco Group Companies.The Saudi Arabian oil company signed downstream MoUs and agreements with Honeywell's  Honeywell UOP, Motiva, NewMarket's  Afton Chemical and ExonMobil . It signed upstream agreements with Sempra's  infrastructure unit, Woodside Energy  and NextDecade .Aramco signed technology and innovation MoUs and agreements with Amazon  and its AWS unit, Nvidia  and Qualcomm . It signed technical services MoUs with SLB , Baker Hughes , McDermott, Halliburton , Nabors , Helmerich & Payne , Valaris , NESR , Weatherford , Air Products and Chemicals , KBR , Flowserve , NOV , Emerson , GE Vernova  and Honeywell.It signed a strategy and corporate development MoU with Guardian Glass, while its subsidiary, Wisayah, reached agreements with PIMCO, State Street  and Wellington. Lastly, it signed agreements for short-term cash investments via","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NESR","HAL.AU","APD","NVIW.SI","NVDD","NVDS","GEV.AU","APD.AU","WDS","SRE","NVDS.UK","HAL","WDS.AU","NEXT","BKR","BLK.AU","2NVD.UK","HON","VAL","WFRD","SNVD.UK","EMR.AU","STT","XOM","NVD2.UK","SLB.AU","NEU","BLK","GEV","NOV.AU","NVDX","NOV","NVDY","FLS","HP","USAW.SI","EMR","NEU.AU","SLB","NESR.AU","NBR","NVDU","KBR","NVD3.UK","VAL.AU","NVD"],"gpt_icon":1},{"id":"2535798189","title":"Neuren Confirms Receipt of US FDA Meeting Minutes for Trial; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535798189","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535798189?lang=en_us&edition=fundamental","pubTime":"2025-05-13 13:46","pubTimestamp":1747115196,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received the official minutes from its Type C meeting with the US Food and Drug Administration, finalizing the co-primary endpoints for its upcoming Phase 3 clinical trial of drug candidate NNZ-2591 to treat Phelan-McDermid syndrome, according to a Tuesday filing with the Australian bourse.The company said it remains on track to start the trial by the middle of the year, pending US FDA protocol review, and confirmed no additional funding is needed, the filing said.Shares of the company rose 3% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2533914044","title":"Neuren Pharmaceuticals Partner Posts 11% Surge in Rett Syndrome Drug Sales in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533914044","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533914044?lang=en_us&edition=fundamental","pubTime":"2025-05-08 10:30","pubTimestamp":1746671432,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its partner Acadia Pharmaceuticals reported first-quarter net sales of $84.6 million in the US for its Rett syndrome drug, Daybue, according to a Thursday Australian bourse filing.The figure represents an 11% increase from last year, the filing said.Acadia, the company's partner for the development and commercialization of the drug, retained the net sales guidance for the current year of between $380 million and $405 million for the US market.The company expects US royalties of AU$62 to AU$67 million for the year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2533691371","title":"BRIEF-Neuren Pharmaceuticals Says Daybue Q1 2025 Net Sales $84.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533691371","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533691371?lang=en_us&edition=fundamental","pubTime":"2025-05-08 09:26","pubTimestamp":1746667594,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Says Daybue Q1 2025 Net Sales $84.6 MillionMay 8 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:DAYBUE Q1 2025 NET SALES US$84.6 MILLIONFurther company coverage: NEU.AX (Reporting by Nichiket  Sunil) ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RF3CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU"],"gpt_icon":0},{"id":"2533996326","title":"Neuren Pharmaceuticals Ltd -  Daybue Q1 2025 Net Sales US$84.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2533996326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533996326?lang=en_us&edition=fundamental","pubTime":"2025-05-08 07:02","pubTimestamp":1746658969,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF3CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2532692829","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532692829","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532692829?lang=en_us&edition=fundamental","pubTime":"2025-05-02 15:03","pubTimestamp":1746169416,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong finish this Friday in what has been a strong week for the share market. By the time the closing bell rang, the ASX 200 had jumped up a healthy 1.13%. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/02/here-are-the-top-10-asx-200-shares-today-02-may-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7145","TLX.AU","NEU.AU","NIC.AU","BK7129","XJO.AU","BK7132","BK7067","PNV.AU","BK7126","LIC.AU","IEL.AU","BK7095","LNW.AU","BK7083","BK7078","SMR.AU","CU6.AU","BK7096","BK7508","BOE.AU"],"gpt_icon":0},{"id":"2532859066","title":"Neuren Pharmaceuticals Appoints Chief Regulatory Officer; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532859066","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532859066?lang=en_us&edition=fundamental","pubTime":"2025-05-02 10:00","pubTimestamp":1746151245,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  appointed Daryl DeKarske as chief regulatory officer, according to a Friday filing with the Australian bourse.DeKarske had regulatory affairs leadership roles at Shire, Acadia, and Horizon Therapeutics, per the filing.Neuren Pharmaceuticals' shares were up 8% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","BK7508","NEU.AU","XJO.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[]}}